Background: Up to 55% of patients who are administered ketamine experience an emergence phenomena (EP) that closely mimics schizophrenia and increases their risk of injury; however, to date, no studies have investigated genetic association of ketamine-induced EP in healthy patients.
K
etamine-induced emergence phenomena (EP) occur in up to 55% of patients treated with ketamine (Kumar, Bajaj, Sarkar, & Grover, 1992; Strayer & Nelson, 2008) . It is characterized by euphoria, vivid dreams, illusions, delirium, and hallucinations (Aroni, Iacovidou, Dontas, Pourzitaki, & Xanthos, 2009; Pomarol-Clotet et al., 2006; Powers, Gancsos, Finn, Morgan, & Corlett, 2015; Xu & Lipsky, 2015) . EP has been equally described as floating sensation with distortions in body images and objects, which correlate with positive and negative psychotic symptoms of schizophrenia (Pomarol-Clotet et al., 2006; Xu & Lipsky, 2015) . Single-photon emission tomographic studies revealed that ketamine produces negative psychotic symptoms by direct inhibition of the N-methyl-D-aspartate receptor (NMDAR; Stone et al., 2008) , whereas positive symptoms correlated with ketamine blood levels and glutamate release from the anterior cingulated cortex (Stone et al., 2008 (Stone et al., , 2012 . Thus, EP may be related to NMDAR function and rate of ketamine metabolism. Beside increasing healthcare cost (Franco, Litaker, Locala, & Bronson, 2001) , EP increases patients' risk of injury, increases length of hospital stay, requires more nursing care, and contributes to patients' lower satisfaction with care (Hudek, 2009; O'Malley, 2014; Stoelting & Hillier, 2005) . Although several medications such as midazolam (Sener, Eken, Schultz, Serinken, & Ozsarac, 2011 ) and propofol (Andolfatto & Willman, 2011) have been used to manage EP, to date there is no definitive treatment or predictive tools to identify patients who will develop EP. As a result, most clinicians avoid using ketamine despite its diverse clinical profile.
Clinical uses of ketamine include induction of anesthesia, procedural sedation, acute and chronic pain management, treatment of depression (Aroni et al., 2009; Mion & Villevieille, 2013; Zarate, Brutsche, Ibrahim, et al., 2012; Zarate, Brutsche, Laje, et al., 2012) , and modulation of inflammation (D'Alonzo et al., 2011; Dale, Somogyi, Li, Sullivan, & Shavit, 2012 . Ketamine is essential in any basic healthcare system (World Health Organization, 2013 ) and has been used in various settings from battlefields (Dickey, Jenkins, & Butler, 2012) , developing countries (Morgan & Curran, 2012) to critical care units in tertiary care centers (Mohrien, Jones, MacDermott, & Murphy, 2014) .
Ketamine is a unique anesthetic that exerts most of its effects by noncompetitive antagonism of the NMDAR. Unlike other anesthetics, such as propofol, patients under ketamineinduced loss of consciousness maintain spontaneous respiration and protective airway reflexes. In addition, it has sympathomimetic (increased heart rate, blood pressure, and cardiac output) and bronchodilatory effects, which makes it the preferred anesthetic in patients with hemodynamic instability, such as hypovolemia, cardiogenic shock and constrictive cardiac disorders (Aroni et al., 2009) , and severe asthma (Lau & Zed, 2001) . It is equally the sedative of choice in situations where airway management equipment is not readily available (e.g., battlefields; Dickey et al., 2012) , developing countries (Morgan & Curran, 2012) , and endoscopy and radiology suites (Mason et al., 2002) . In addition, ketamine has been widely used to provide sedation and analgesia in burn units and emergency departments. The major advantage of ketamine in these units lies not only in its analgesic effects but also in the fact that it can be administered intramuscularly, orally, rectally, and transnasally. This is desirable in uncooperative children and patients with extensive burns who may have limited intravenous access.
Although the causes of adverse drug reactions are multifactorial, genetic predisposition has been estimated to cause about 50% of severe adverse drug reactions and account for up to 95% of drug response variability (Chidambaran, Ngamprasertwong, Vinks, & Sadhasivam, 2012) . Ketamine exerts most of its clinical effects by noncompetitively binding to the NR2 subunit of the NMDAR and blocking the excitatory effects of glutamate (its principal neurotransmitter). Genetic polymorphism of the NMDAR gene (GRIN2) has been associated with NMDAR hypofunction, psychotic symptoms, and memory disorders (Frohlich & Van Horn, 2014; Li & He, 2007; Xu & Lipsky, 2015) . Two single-nucleotide polymorphisms (SNPs; T200G [rs1019385] and 4197T/C [rs1806194]) in the GRIN2B gene have been linked to schizophrenia in susceptible individuals (Demontis et al., 2011) . Thus, ketamine-induced EP may be related to genetic alternations in the NMDAR-NR2B subunit.
In addition, ketamine is metabolized primarily by enzymes coded by CYP2B6 gene (Hijazi & Boulieu, 2002; Yanagihara et al., 2001) . Besides disease conditions such as infection and inflammation (Cheng & Morgan, 2001; Renton, 2005) , SNPs in drug metabolizing enzymes can alter drug metabolism . CYP2B6*6 is a loss of function allele that has two nonsynonymous SNPs, Gln172His (rs3745274, c.516G>T) and Lys262Arg (rs2279343, 785A>G), in exons 4 and 5, respectively. CYP2B6*6 allele significantly affects ketamine metabolism (Li et al., 2013) and has been associated with increased drowsiness in patients with chronic pain (Li et al., 2015) . However, to date, no study has investigated the genetic associations between CYP2B6 and GRIN2B alleles and EP in relatively healthy patients.
Purpose
The primary objective of this pilot study was to explore genetic association between CYP2B6 and GRIN2B SNPs and the incidence and severity of ketamine-induced EP in relatively healthy patients. Secondary aims included determination of the effect size of EP and effect of EP on patient satisfaction.
METHODS

Participants and Settings
Participants were recruited from an ambulatory surgical center and a community hospital, which are affiliated with a large academic medical center in central Massachusetts. Patients deemed relatively healthy were eligible to participate (American Society of Anesthesiology physical status classes [ASA I and ASA II]); ≥18 years; undergoing minor orthopedic hand, foot, or anorectal surgery under sedation; able to read, write, and understand English; and able to give informed written consent. ASA I patients are considered "normal healthy" patients, whereas ASA II patients are those with mild systemic disease but without substantive functional limitations. Examples include (but are not limited to) current smoker, social alcohol drinker, pregnancy, obesity (body mass index [BMI] between 30 and 40), well-controlled diabetes mellitus/hypertension, and mild lung disease. Patients with liver diseases that can affect drug metabolism or elevated liver enzymes are classified as ASA III or above and thus are not included in this study. Patients were excluded if they had a diagnosis of depression, schizophrenia, or bipolar disorder. Patients taking medications known to induce or inhibit the activity of CYP2B6 enzymes, such as rifampin, dilantin, and phenobarbital, were also excluded. A total of 135 patients were approached to participate, 88 were enrolled, and 75 completed the study (Figure 1 ). Thirteen participants either dropped from the study because of conversion to general anesthesia or unwillingness to continue the study.
Procedures
The study was approved by the University of Massachusetts Medical School Institutional Review Board. An institutional review board waiver was obtained to access the operating room schedule to screen for potential participants. During the preoperative period, the admitting nurse introduced the study to the patients, and those interested were then introduced to the principal investigator (PI) who discussed the study, answered all questions, and obtained informed written consent prior to the scheduled surgery and before the administration of any sedatives or hypnotics. After providing written informed consent, participants completed a demographic questionnaire. Patients underwent their scheduled surgery, and all decisions regarding type and dose of anesthetic were determined by the anesthesia provider. Those given intraoperative ketamine received a dose of ≥0.5 mg/kg-as is standard for these procedures. The specific dose and use of other perioperative medications was at the discretion of the anesthesia provider. Within 1 hour of arrival to the postanesthetic care unit, the Clinician Administered Dissociative State Scale (CADSS) was administered by the PI. Information about perioperative medications was abstracted from the medical record, and a blood sample was obtained from the existing intravenous line or by direct venous puncture. Blood was stored at −80°C until DNA extraction.
Measurements and Phenotyping
All data were entered directly into Research Electronic Data Capture (REDCap), a secure Web-based application for managing online surveys and databases for research. Demographic data included age, gender, ethnicity, race, education, smoking status, and alcohol consumption. The CADSS was used to evaluate ketamine-induced EP. CADSS scores range from 0 to 112, with scores ≥4 indicating positive dissociation and higher scores indicating increase severity of dissociation (Bremner, 2014) . Reliability estimated using Cronbach's alpha was .94 (Bremner et al., 1998) . To assess the incidence of EP, scores were recoded; total CADSS scores of less than 4 was considered to be EP negative, whereas a total CADSS score of ≥4 was considered to be EP positive. The severity of EP was a continuous variable, with higher CADSS scores indicating more EP.
We also recorded administered ketamine dosage, other perioperative medications given, and overall satisfaction with anesthesia care. As is common practice in these facilities, 98% of participants received preoperative midazolam. Prior to discharge from the postanesthesia care unit, each participant was asked to rate their satisfaction with the anesthetics on a scale of 0 to 100-with 0 indicating total dissatisfaction and 100 indicating total satisfaction. In addition, participants were asked to indicate their willingness to accept the same anesthetics in the future as "yes," "I don't know," or "no."
Genetic Data
Gene/SNP Selection Gene/SNP selection for analysis was driven by the literature. Ketamine is metabolized primarily by enzymes coded by the CYP2B6 with minor contributions from the CYP2C9 and CYP3A4 (Hijazi & Boulieu, 2002; Yanagihara et al., 2001) . CYP2B6 has many functional SNPs that alter drug action . Specifically, CYP2B6*6 haplotype has two SNPs that result in nonsynonymous amino acid substitutions, Gln172His (rs3745274, c.516G>T) and Lys262Arg (rs2279343, 785A>G), in exons 4 and 5, respectively . In vitro studies show that CYP2B6*6 allele significantly alters ketamine metabolism (Li et al., 2013) . Recently, among patients with chronic pain, the CYP2B6*6 allele has been associated with decreased ketamine clearance and increased drowsiness (Li et al., 2015) .
Ketamine is primarily an NMDAR antagonist. It binds to the NR2 subunit of the NMDAR and blocks the action of glutamate. Functional magnetic resonance imaging studies have shown that ketamine induces the release of glutamate in a manner similar to that seen in NMDAR hypofunction (Frohlich & Van Horn, 2014) . NMDAR hypofunction and glutamate hyperactivity are the molecular bases of schizophrenia (Javitt, 2010) . In addition, genetic polymorphisms in the glutaminergic pathway have been associated with NMDAR hypofunction and symptoms of schizophrenia, and learning and memory disorders (Frohlich & Van Horn, 2014; Li & He, 2007; Xu & Lipsky, 2015) . Two SNPs (T200G [rs1019385] and 4197T/C [rs1806194]) in the NMDAR gene (GRIN2B) have been linked to schizophrenia in susceptible individuals (Demontis et al., 2011; Li & He, 2007) . Thus, ketamine-induced EP may be related to NMDAR-NR2B subunit function. Two candidate SNPs from the CYP2B6*6 and GRIN2B genes were selected for analysis.
Blood Collection and Genotyping
Of the 47 participants who received ketamine, venous blood was collected from 45 participants into ethylenediaminetetraacetate (EDTA) vacutainer tubes and stored at −80°C until DNA extraction. Genomic DNA was extracted from the blood using the QIAgen Protocol for DNA purification from blood (QIAamp DNA Blood Mini Kit, Cat. No 51104). CYP2B6 SNPs (rs3745274 and rs2279343) and GRIN2B SNPs (rs1019385 and rs1806191) were genotyped using standard Taqman Genotyping Assays (Applied Biosystems). All samples were run against control standards (two nontemplate controls and two known genotype controls-one male and one female from the Center d'Étude du Polymorphisme Humain) pedigree sample. As an additional control, two study samples were randomly selected and regenotyped for each of the SNPs.
DNA extraction was performed at the University of Massachusetts Medical School Disease Conquering biorepository, whereas genotyping was performed at the Duke University Molecular Physiology Institute. Purity and quantification were assessed by measuring the optical density at 260 nm. Laboratory personnel doing the genotyping were blinded to the EP status.
Statistical Analysis
Genotype frequencies of all SNPs were tested for HardyWeinberg equilibrium (HWE) using the chi-square test. We performed statistical analyses using SPSS Version 22 (IBM Corporation, Armonk, New York). Demographic characteristics were summarized using frequencies and percentages (gender, race, ethnicity, and level of education), and means and standard deviations (age and BMI). Differences in demographic variables between ketamine versus nonketamine, and EP positive versus EP negative cases were tested using Fisher's exact test, t-test for independent samples, and Mann-Whitney U-test.
Among ketamine recipients, Fisher's exact test was used to evaluate associations between EP occurrence (0 = no, 1 = yes) and each SNP using the dominant genetic model. In the dominant model, we tested the effect of having at least one copy of the risk alleles in the SNP on the occurrence of EP. For instance, for the CYP2B6 G>T SNP, participants with risk allele genotypes (G/T and T/T) were combined and compared against homozygous wild-type (G/G) participants for EP occurrence. Logistic regression modeling was used to determine the main effect of each genotype on EP occurrence, then adjusting for different variables: age, BMI, gender, ethnicity, level of education, ketamine dose, midazolam dose, propofol dose, duration of surgery, and time from ketamine administration to assessment of dissociation. Nonstatistically significant predictors were excluded from the model, whereas significant covariates (age, ketamine dose, duration of anesthesia, and time from ketamine administration to assessment of dissociation) were used to evaluate the relationship between genotype and EP occurrence. Ninety percent confidence intervals for risk prediction were estimated from the logistic regression model. Severity of EP was predicted using linear regression modeling adjusting for the same significant covariates. The total CADSS score (severity of EP) was square root-transformed to account for right skewness, and the residuals were normally distributed. Collinearity of covariates was tested, and all covariates in the model had a variance inflation factor of less than 4.
The additive genetic model (that test effect of each risk allele in the SNP in a linear fashion, such that having one risk allele [G/T] has a greater effect than having no risk alleles [G/G], and having two risk alleles [T/T] has a greater effect than having only one [G/T]) was not tested because of low cell count. Potential interaction with midazolam and propofol were not investigated because 98% of patients received both midazolam and propofol. Given the small sample size limiting power, p-values of less than .10 were considered statistically significant as recommended for pilot studies (Cohen, 1994) .
RESULTS
Participant Characteristics
The total sample included 35 men and 40 women with a mean age of 50.5 years (SD = 13.9). Demographic characteristics are reported in Table 1 . Of the 75 participants, 47 received ketamine. The average dose of intravenous ketamine administered was 0.54 mg/kg (SD = 0.19). There were no statistically significant differences between those who received ketamine and those who did not, in terms of BMI, gender, race, ethnicity, and educational level (p > .10). Of the 47 participants who received ketamine, 19 (40.4%) experienced EP (cases), whereas 28 (59.6%) did not (controls). Among those who received ketamine, there was no statistically significant difference between age, BMI, gender, race, ethnicity and educational level, and the occurrence of EP (p > .10).
Clinician Administered Dissociative State Scale
For our sample, reliability of CADSS estimated using Cronbach's alpha was .82. As expected, the average total CADSS score of participants who did not receive ketamine was lower (M = 1.0, SD = 1.78) than those of participants who received ketamine (M = 4.7, SD = 5.59). This difference was statistically significant (MannWhitney U = 328.0, p < .001). The odds of developing EP were 8.8 times higher in patients exposed to ketamine compared to those who were not (90% CI [2.34, 32.44]). There was a statistically significant relationship between ketamine administration and EP occurrence (p = .003, Fisher's exact test). This relationship was still significant after controlling for age, duration of surgery, and time from ketamine administration to assessment of EP (p = .002). The odds of EP occurring increased by 1.14 for every 1 mg increase in the dose of ketamine (90% CI [1.06, 1.21]). There was no statistically significant relationship between BMI and total CADSS score (r = −.13, p = .27). The total CADSS score did not differ significantly between men and women (U = 670.5, p = .75). Performance on CADSS-scored dichotomously-was not related to BMI or gender (p = .80, Fisher's exact test).
Candidate Gene Analysis for EP
As summarized in Table 2 , samples were successfully genotyped for CYP2B6*6 (rs3745274 and rs2279343) and two GRIN2B (rs1019385 and rs1806191) alleles. All SNPs were in HWE in both EP positive (cases) and control groups, except rs1019385 in the control group (minor allele frequencies [MAF] 0.46, p = .02). As such, we reran the analysis using Caucasian-only participants and the difference between the observed and expected MAF was still significant (p = .04). With a 96% successful call rate of genotyping, this deviation from HWE may be related to the small cell count. A metaanalysis found that deviation from HWE occurs in about 10% case-control genetic association studies but does not postulate dismissal of the findings of the association studies (Trikalinos, Salanti, Khoury, & Ioannidis, 2006) . No significant difference was observed in the genotype distribution of the four SNPs between cases and controls. Fisher's exact probability testing of relationship between EP occurrence and genotype (in dominant genetic model) was not statistically significant in all SNPs: rs3745274, rs2279343, rs1019385, and rs1806191 (p = 1.00, .76, .71, and .74, respectively).
Assessment of Model Fit
Model fit analyses were completed to determine the nongenetic covariates. Age, ketamine dose, duration of anesthesia, and time from ketamine administration to assessment of EP produced the best fit for predicting EP occurrence by genotype (Table 3) . Other potential factors affecting EP, such as liver function and concurrent patient use of CYP inducers and inhibitors, were controlled for by subject exclusion criteria. All models that included an SNP (rs3745274, rs2279343, rs1019385, and rs1806191) could reliably distinguish between EP cases and 
Gender ( controls (cutoff value = 0.5). Nagelkerke's R 2 indicated a moderately strong relationship between prediction and grouping, with overall successful prediction rate of over 77%. Age, duration of anesthesia, ketamine dose, and time from ketamine administration to assessment of EP made a significant contribution to the prediction (p < .10), whereas genotype was not a significant predictor of EP status (p > .10). When genotype was removed from the model, all nongenotype predictors (ketamine dose, age, duration of anesthesia, and time from ketamine administration to assessment of EP) still made statistically significant contributions to the model (p < .10). There was no statistically significant interaction between ketamine dose and duration of anesthesia (p = .98), ketamine dose and time from ketamine administration to assessment of EP (p= .81), and duration of anesthesia and time from ketamine administration to assessment of EP (p = .86). Note. Model 5 is the baseline model without candidate SNP used for prediction. Nagelkerke's R 2 is shown in the model summary for all models. AOR = adjusted odds ratio; CADSS = Clinician Administered Dissociative State Scale; CI = confidence interval; SNP = single-nucleotide polymorphism. Total CADSS scores ranged from 0 to 22 (M = 4.74, SD = 5.59). There was no statistically significant relationship between EP severity and genotype (dominant model). A linear regression was developed to predict severity of EP based on age, duration of anesthesia, ketamine dose, and time from ketamine administration to assessment of EP. The regression was significant (F 4,42 = 4.03, p = .007)-with an adjusted R 2 of 21%. Age, dose of ketamine, duration of anesthesia, and time from ketamine administration to assessment of EP made significant contributions to the model (Table 4) .
Exploring EP and Satisfaction With Care
Overall, the participants reported over 96% satisfaction with the anesthetics. There was no difference in satisfaction between those who received ketamine and those who did not (t 73 = −0.92, p = .36). In addition, 71 participants (94.7%) responded "yes," two (2.7%) responded "I don't know," and two (2.7%) responded "no" when asked about their willingness to accept the same anesthetic in the future. Among patients who received ketamine, 97.9% (n = 46) were willing to accept the same anesthetics in the future. Interestingly, EP occurrence did not affect satisfaction with anesthesia care (MannWhitney U = 240, p = .42) or willingness to accept the same anesthetics (p = .40, Fisher's exact test).
DISCUSSION
To our knowledge, this is the first study to examine the relationship between ketamine-induced EP and genetic polymorphisms in the pharmacokinetic (CYP2B6) and pharmacodynamic (GRIN2B) pathways of ketamine in relatively healthy patients (ASA I and ASA II). Ketamine-induced EP occurred in 40.4% of the patients who received ketamine-consistent with the range reported in the studies of Kumar et al. (1992) and Strayer and Nelson (2008) . Our small sample of patients experiencing EP (n = 19) likely limited our ability to demonstrate a significant association between ketamine-induced EP occurrence and CYP2B6 (rs3745274 and rs2279343) and GRIN2B (rs1019385 and rs1806191) SNPs. Previous studies reported lack of association between CYP2B6 SNPs and EP in patients with treatment-resistant depression (Zarate, Brutsche, Laje et al., 2012) and chronic pain (Li et al., 2015) . However, on the basis of our sample size estimates, these studies were underpowered.
In addition to low power, one potential reason for lack of association may be the pathophysiological effect of diseases, such as obesity, inflammation, infection, and diabetes on the phenotypic expression of CYP2B6 gene. These disease conditions affect CYP expression and activity and thus may alter drug metabolism and disposition (Cheng & Morgan, 2001; Renton, 2005) . The influence of infection and inflammation is of particular interest because many patients in this study underwent anorectal surgery for excision of hemorrhoids (a chronic inflammatory disease with risk for infection). Future genetic studies of the metabolism of ketamine or ketamine-induced EP should consider assessing the impact of inflammatory markers, diabetic control (glycosylated hemoglobin), and obesity.
Nongenetic variables (younger age, ketamine dose, duration of anesthesia, and time from ketamine administration to assessment of dissociation) appear to predict the occurrence and severity of ketamine-induced EP. It is traditionally believed that EP is more common in women, patients over the age of 16, short operative procedures, those receiving large doses, and with rapid administration (Frohlich & Van Horn, 2014; Strayer & Nelson, 2008 ). Our logistic model correctly predicted the occurrence of EP 77% of the time and accounted for about 44% of its variance. Some surprising findings emerged from this model: Gender was not a significant predictor of EP, and among adults, EP occurrence decreased with age. We speculate that this observation may be due to the fact that, for procedural sedation, ketamine is typically administered at the start of surgery (just prior to injection of local anesthesia). Thus, although the dose is titrated to effect (amount needed to tolerate the noxious stimuli), it is not related to the duration of the procedure. Despite the fact that the average dose of ketamine administered was 0.54 mg/kg, (which is a "low" or "subanesthetic" dose), ketamine dose remained a significant predictor of EP, even after adjusting for BMI, age, duration of procedure, and time from ketamine administration to assessment of dissociation. This may have direct clinical implications because, for every 1mg of ketamine administered, the odds of developing EP increased by a factor of 1.135-even with lower baseline doses. Adequately powered future studies are needed to support whether anesthesia providers should change current practice. However, our preliminary findings suggest that administration of just 1 ml (10 mg) of ketamine increased the odds of developing EP by a factor of 3.52.
EP occurrence did not affect patient-reported satisfaction with the anesthesia care. This observation is contradictory to previous studies (Strayer & Nelson, 2008) and prevailing clinical belief. This may be due to the fact that hallucination and delirium have been used as proxies for dissatisfaction with care. Anecdotal evidence gathered during the assessment of dissociation revealed that most patients "enjoyed" the dissociative state; however, the nurses "disliked" patients experiencing EP. We speculate that dissatisfaction with EP may reflect "provider's dissatisfaction" with patients' reaction and not patients' dissatisfaction with the experience or care. In a future study, it would be interesting to compare patients' and nurses' perceptions of ketamine-induced EP. Another plausible explanation of the lack of dissatisfaction could be the coadministration of midazolam and propofol. Previous studies have reported decreased incidence of EP with midazolam (Sener et al., 2011) and propofol (Andolfatto & Willman, 2011) administration. However, it is possible that coadministration of these medications with ketamine may convert the dissociative symptoms from frightful, unpleasant hallucinations and delusions to pleasant dreams. Future studies could investigate the symptomology of EP from ketamine alone versus ketamine and propofol/ midazolam coadministration.
This study provides preliminary data to inform a fully powered pharmacogenetic study investigating ketamine-induced EP. Using Quantos (Gauderman, 2002) , we have estimated sample size requirements for future genetic association studies based on our observed MAF, genotype effect sizes, assuming a dominant genetic model (Table 5) . For instance, a genetic association study of EP occurrence by CYP2B6*6 allele using the dominant genetic model will require 390 cases and 390 controls to achieve a power of 80% (Gauderman, 2002) . Adequate sample size is one of the most important requirements of a quality pharmacogenetic association study. Besides effect size, the sample size of a pharmacogenetic study must take into account the MAF, genetic model of inheritance (dominant, recessive, codominant, additive, or multiplicative) , and the number of subgroups to be analyzed. Generally, at the same relative risk and significance level, SNPs with larger MAF will require lower sample size than those with smaller MAFassuming the same model of inheritance. Similarly, SNPs inherited by a dominant model will require smaller sample sizes compared with those inherited by recessive or additive model (assuming the same phenotype prevalence, MAF, complete linkage disequilibrium, and significance level). Given the complexity of sample size determination in genetic association studies, software such as Quantos (Gauderman, 2002) has been developed. Nurse scientists carrying out genetics or pharmacogenetics association studies are encouraged to consults biostatisticians trained in genetic analyses or use one of these software.
Lessons Learned
Lessons learned from this pilot study may help the completion of a fully powered study. As expected, cost and infrastructure are major barriers to completing any pharmacogenetic study. Laboratory space, equipment, storage, and sample processing may be at a premium for many investigators-even if the PI is at a Clinical Translational Science Award-supported campus.
The first step in designing a pharmacogenetic association study is to clearly and accurately define the phenotype of interest (an adverse drug reaction, a desired effect, side effect, etc.). Carefully defining the phenotype will improve internal validity, reduce confounding, and improve power to detect association. For this study, although our phenotype, EP, has been described extensively in the literature, no instrument has been developed specifically to measure EP. As a result, proxies such as patients' dissatisfaction, dreams, and instruments used to assess delirium have been used to measure EP. The CADSS was developed to measure dissociative states in post-traumatic stress disorder but has been used in studies of ketamine-induced EP. Prior to data analysis, we verified the ability of CADSS to distinguish ketamine-induced EP from other postanesthetics behavior (on average, patients who received ketamine scored higher on CADSS than nonketamine recipients). Thus, cases and controls for preliminary pharmacogenetics studies may include the exposed (cases) and unexposed (controls) and, among those exposed to the drug, those with EP (true cases) compared to those without EP (true controls).
Once the sample size and phenotype are clearly determined, samples for a pharmacogenetic study can be collected in a clinical setting (here, an ambulatory surgical center). Samples for this study were collected into EDTA tubes from existing intravenous line prior to removal of the line. In cases where aspiration of the intravenous access failed to return blood, direct venous puncture was performed by the PI. Leukocyte DNA is stable in EDTA at 4°C for 72 hours, and even much longer when stored at −80°C. The samples were collected over a 6-month period and stored at −80°C in a molecular pharmacology laboratory. DNA extraction and genotyping were outsourced to university-based core laboratory facilities. Using the services of a core facility may not only improve the quality of the analysis but also equally reduce cost.
As expected, having a multidisciplinary team was essential to the success of this pilot project. Our team included a nurse anesthetist PI, two nurse scientists (one with genetics expertise), and a biostatistician, with consultation from a molecular pharmacologist. In addition, advice was sought from physician anesthesiologists. This multidisciplinary team ensured that all critical aspects of the study were possible. Prior to starting recruitment, the study was presented to surgeons, nurses, and anesthesia providers in the recruitment facilities. This buy-in was critical for recruitment of participants. Finally, potential participants were reassured that, throughout the study, their clinical care superseded the research efforts. Note. AOR = adjusted odds ratio; dbSNP = single-nucleotide polymorphism database; MAF = minor allele frequency; OR = gene only odds ratio for emergence phenomenon occurrence.
a Sample size for cases only (match for control to obtain total sample size), assuming dominant genetic model. Odds ratio for EP occurrence by genotype adjusted for ketamine dose, age, duration of anesthesia, and time from ketamine administration to assessment of dissociation.
Limitations and Strengths
Several limitations need to be acknowledged. First, internal validity of the study was diminished by the high rate of coadministration of midazolam (as a common anesthesia practice) among participants who received ketamine. As previously discussed, this could not be overcome in this current study design. Future studies should address this limitation in the design, as this pilot was not approved for a randomized controlled trial. Second, being a pilot study, the sample size was small, and most of the patients were Caucasian, middle aged, and well educated. These participant demographics limit the external validity or generalizability of the study findings. A larger sample is needed to increase the power to detect differences in genotype in future studies (Table 5 ). It is possible that other, unstudied SNPs in the CYP2B6 and GRIN2B genes may be associated with ketamine-induced EP. Unfortunately, no data were collected on ketamine metabolite concentrations, limiting our ability to draw direct conclusions about the influence of CYP2B6 genotype on ketamine metabolism.
Despite the limitations, this study had several strengths. Notably, participants were well characterized with stringent inclusive and exclusive criteria, thus reducing the number of variables that could affect ketamine metabolism (e.g., history of severe medical history, i.e., ASA > II) and occurrence of EP (e.g., history of depression and schizophrenia). In addition, the CADSS tool was administered by one observer (PI), thereby reducing concerns of interobserver variability. Finally, study occurred in a real clinical setting, which improves the generalizability of the findings.
Conclusions
Our results supported some known evidence regarding nearly ninefold increased risk of EP occurrence with ketamine exposure and dose-dependent risk of EP occurrence and severity. Given these findings, close monitoring of patients undergoing or recovering from procedural sedation with ketamine by nurses is strongly recommended. This is especially important for younger adults receiving large doses of ketamine for relatively short procedures-who are more likely to experience EP. Conversely, some of our findings may offer evidence to potentially challenge current assumptions about patient satisfaction with care provided and EP occurrence. Although patients experiencing EP may produce a negative experience for providers and may be at risk of injury, ketamine-induced EP did not affect patient-reported satisfaction with care. This pilot study provided proof of feasibility, as well as preliminary insights into the potential pharmacogenetic and nongenetic influences on ketamine-induced EP. Further studies are necessary to improve the evidence behind this phenomenon.
